An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)
- First Posted Date
- 2015-10-12
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 3
- Registration Number
- NCT02574260
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
- Conditions
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 31
- Registration Number
- NCT01368276
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 5
- Registration Number
- NCT01161498
- Locations
- 🇬🇧
The Royal Marsden Hospital, London, United Kingdom
🇺🇸Medical Univesity of South Carolina, Charleston, South Carolina, United States
🇺🇸VCU Massey Cancer Center, Richmond, Virginia, United States
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 437
- Registration Number
- NCT00769704
- Locations
- 🇺🇸
MD Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 17
- Registration Number
- NCT00402025
- Locations
- 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸Mary Crowely Medical Research Center, Dallas, Texas, United States
🇺🇸UCI Medical Center, Orange, California, United States
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
- First Posted Date
- 2006-02-09
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- BioVex Limited
- Target Recruit Count
- 50
- Registration Number
- NCT00289016
- Locations
- 🇺🇸
Mountainside Hospital, Montclair, New Jersey, United States
🇬🇧Royal Marsden Hospital, London, United Kingdom
🇺🇸UCLA, Los Angeles, California, United States